Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Brontictuzumab + Trifluridine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Brontictuzumab | OMP-52M51 | NOTCH1 Antibody 2 | Brontictuzumab (OMP-52M51) is a monoclonal antibody that binds Notch1 and prevents ligand interaction and pathway activation, which may inhibit angiogenesis and tumor growth (PMID: 23774673, PMID: 31616059, PMID: 29726923). | |
Trifluridine | F3DThd | FTD|trifluorothymidine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03031691 | Phase I | Brontictuzumab + Trifluridine | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |